About the job
Avalyn Pharma is innovating the landscape of pulmonary fibrosis treatment through a groundbreaking pipeline of inhaled formulations. These approved medications are expertly designed to minimize systemic exposure and deliver targeted therapy directly to the affected areas. Pulmonary fibrosis, characterized by lung tissue scarring, diminishes lung function and quality of life, contributing to increased mortality rates. Conventional therapeutic options may slow disease progression but often come with significant toxicities that limit their application. Avalyn’s inhaled approach directly addresses the underlying causes of pulmonary fibrosis, aiming to enhance patient outcomes with reduced systemic side effects. Currently, Avalyn’s AP01, an optimized inhaled formulation of pirfenidone, is under investigation in the MIST Phase 2b study for progressive pulmonary fibrosis (PPF). This formulation has demonstrated clinical proof-of-concept with better efficacy and safety profiles compared to existing treatments, having been evaluated in over 150 patients with various forms of pulmonary fibrosis. Furthermore, Avalyn has completed two Phase 1 studies for AP02, an inhaled formulation of nintedanib for idiopathic pulmonary fibrosis (IPF), with plans for a Phase 2 clinical trial in the works. For more details, please visit avalynpharma.com and follow us on LinkedIn.
